Podcasts about krakow

Lesson 4When the exception is the lawExplore unexpected rulings that reveal the hidden fallback mechanisms built into Jewish law. These cases show how the law itself protects deeper values like human dignity and family harmony. Cases PAVIA, 1450; SALONIKA, 1550; KRAKOW, 1570; LIOZNA, 1790

Alex Moss and Burton DeWitt are back with a new episode of your go-to darts podcast after a busy week of action on the PDC ProTour!   The boys start off the show with a look back at the Poland Darts Open, the first PDC European Tour event to be held in Poland, and discuss how Luke Littler's title-winning campaign in Krakow compares to the best ever in European Tour history.   Aden Kirk (20:02) joins the show ahead of making his UK Open return in Minehead next weekend. The former PDC tour card holder looks back on his career in the game so far, from bursting onto the scene at the 2014 UK Open and beating Phil Taylor on his TV debut to then taking some time away from the sport to start a family, winning on the Challenge Tour in 2024, becoming a children's book author and winning through the PDC In The Community Qualifiers in Alfreton to secure a third appearance in The FA Cup of Darts next week.   Alex and Burton continue their review of the last seven days with a look back at this week's Players Championship double header in Leicester, which saw Ross Smith and Gerwyn Price win the titles, Andrew Gilding make a final and Beau Greaves throw the first nine-dart leg by a female player on the PDC ProTour.   James Beeton (53:57) calls in ahead of his UK Open debut in Minehead next week. The recently-crowned Scottish Open champion reflects on the last few years on the oche, from qualifying for Lakeside for the first time in 2024 and winning his first senior WDF title at the Denmark Open to having his best year to date on the Development Tour in 2025, qualifying for the UK Open for the first time and rising up the ranks in the WDF and making the quarter-finals at Lakeside last year.   The boys finish up the show with a look back at the 2026 PDC Development Tour opening weekend in Leicester and pick out the players who caught their eye, before discussing Mitchell Lawrie becoming the youngest WDF #1 at just 15 years and 110 days old and whether that record will ever be broken.   Join the Darts Strava King group on Strava *** Get your own Alex Moss replica shirt (as worn by our co-host at the Las Vegas Open 2026) from DJD here! A % of the profits will be donated to The Ethan King Fund for Ewing Sarcoma Research *** This podcast is brought to you in association with Darts Corner - the number one online darts retailer! Darts Corner offers the widest selection of darts products from over 30 different manufacturers.  This podcast is sponsored by Darts Atlas - the platform for darts players, venues, and organisations. Darts Atlas is the home of the Amateur Darts Circuit (ADC) with hundreds of tournaments held on the platform every week.  Have you used Darts Atlas before? Share your feedback and experiences with Darts Atlas with us by sending an email to weeklydartscast@gmail.com and be in with a chance of winning some new logo Weekly Dartscast stickers! Check out Condor Darts here: UK site *** Enjoy our podcast? Make a one-off donation on our new Ko-Fi page here: ko-fi.com/weeklydartscast Support us on Patreon from just $2(+VAT): patreon.com/WeeklyDartscast Thank you to our Patreon members: Phil Moss, Gordon Skinner, Connor Ellis, Dan Hutchinson

Send me feedback!A bill review with a guest! Joshua Krakow joins me to discuss a bill he's been helping with here in Florida, "HB 1391 - Family Court Report Cards."Family law statutes already establish timelines and procedural expectations. The Family Court Report Card Act measures how those standards function in practice across the state. It gives lawmakers in Tallahassee reliable information to assess whether existing laws are working as intended and reassures the public that the government is willing to examine itself honestly.SUPPORT JOSHUAJoshua on YouTubeJoshua on FacebookSUPPORT THE SHOWGet a 10% discount by using the code LibertyDad at Black Guns Matter shop.OR, use the referral linkFIND ME ELSEWHERELinktreeSHOW NOTESHB 1391The FloridianSupport the show

Beating an authoritarian regime at the ballot box is hard, but rolling back its changes is harder. Just look at Poland. This episode was produced by Miles Bryan, edited by Jolie Myers, fact checked by Andrea López-Cruzado, engineered by Patrick Boyd and David Tatasciore, and hosted by Noel King and Miles Bryan with special thanks to Grzegorz Sokol. It was supported by a grant from Protect Democracy. Vox had full discretion over the content of this reporting. Rafal Trzaskowski, the mayor of Warsaw, at a campaign rally in Krakow. Photo by Beata Zawrzel/NurPhoto via Getty Images. Listen to Today, Explained ad-free by becoming a Vox Member: vox.com/members. New Vox members get $20 off their membership right now. Transcript at ⁠vox.com/today-explained-podcast.⁠ Learn more about your ad choices. Visit podcastchoices.com/adchoices

Send a textIn our last episode after escaping the Cerulean's Palace, Captain Flashman, Eve and Dr Commander, Dr Krakow tried to find a hiding place from Carl's patrols at a cottage but the Freeman owner refused to let them enter. Meanwhile back at palace Carl must decide what to do with Cerulean now that he's rescued her. Will Carl restore Cerulean's memory or will he leave her a victim of Forgetium? And what about Captain Flashman? Will Carl's crack team of scouts find Captain Flashman and the gang before they find a place to hide? Episode Website: https://captainflashmandefenderoftheuniverse.buzzsprout.comTo keep up to date on all Captain Flashman news, follow him on Facebook and Instagram.This episode stars:Melyssa Ade as Little Chester and VulkarenGene Abella as the Soldier and Captain CredoSam Agro as Chief Magician Carl and the AnnouncerSean Browning as Captain FlashmanDave Healey as Khan The CruelVicki Jenkins as Dr Krakow and Princess HaloJane Luk as Queen Cerulean and TanyaAnn McDougall as EveBrian Webber as the Freeman and the Radio OperatorMusic by Jeff RosenthalProduced, Directed and Written by Dave HealeyAssociate Producer Vicki Jenkins Episode Recorded, Mixed and Soundscape Design by Dave HealeyIntro and Outro Designed by Dave Healey and Dylan Shropshire and Mixed by Dylan Shropshire© Dave Healey 2026Support the showCaptain Flashman Fighting Evil Since 2023

For nearly 10 years, Poland's authoritarian government chipped away at the county's freedoms. Here's how Poles mobilized to get their democracy back before it was too late. This episode was produced by Miles Bryan, edited by Jolie Myers, fact checked by Andrea López-Cruzado, engineered by Patrick Boyd and David Tatasciore, and hosted by Noel King and Miles Bryan. It was supported by a grant from Protect Democracy. Vox had full discretion over the content of this reporting. A march in Krakow, Poland to commemorate the 81st anniversary of the outbreak of the Warsaw Uprising. Photo by Klaudia Radecka/NurPhoto via Getty Images. Listen to Today, Explained ad-free by becoming a Vox Member: vox.com/members. New Vox members get $20 off their membership right now. Transcript at ⁠vox.com/today-explained-podcast.⁠ Learn more about your ad choices. Visit podcastchoices.com/adchoices

Alex Moss and Burton DeWitt are back with a new episode of your go-to darts podcast after the latest Players Championship double header in Wigan!   The boys start off the show with a look back at this week's ProTour action which saw Chris Dobey and Luke Humphries win their first titles of the season.   New PDC tour card holder Carl Sneyd (19:05) joins the show ahead of making his European Tour debut in Krakow this weekend. 'Bomber' chats through his journey in darts so far, from calling time on his rugby league playing days and picking up darts, rising through the ranks at a local level and then a breakthrough title on the Challenge Tour last year, which saw him earn multiple call ups to the PDC ProTour as a top-up player, before securing his first-ever PDC tour card at UK Q-School last month.   New PDC referee Owen Binks (56:13) calls in ahead of his PDC European Tour debut as a referee at the Poland Darts Open this weekend. Owen reflects on the last few years, from how a phone call from the legendary referee George Noble led to him becoming a regular referee on the MODUS Super Series, to learning how to be a spotter and earning a call up to spot for Sky Sports, and then taking on a new role as a PDC referee on stage this year following George's retirement last month.   Join the Darts Strava King group on Strava *** Get your own Alex Moss replica shirt (as worn by our co-host at the Las Vegas Open 2026) from DJD here! A % of the profits will be donated to The Ethan King Fund for Ewing Sarcoma Research *** This podcast is brought to you in association with Darts Corner - the number one online darts retailer! Darts Corner offers the widest selection of darts products from over 30 different manufacturers.  This podcast is sponsored by Darts Atlas - the platform for darts players, venues, and organisations. Darts Atlas is the home of the Amateur Darts Circuit (ADC) with hundreds of tournaments held on the platform every week.  Have you used Darts Atlas before? Share your feedback and experiences with Darts Atlas with us by sending an email to weeklydartscast@gmail.com and be in with a chance of winning some new logo Weekly Dartscast stickers! Check out Condor Darts here: UK site *** Enjoy our podcast? Make a one-off donation on our new Ko-Fi page here: ko-fi.com/weeklydartscast Support us on Patreon from just $2(+VAT): patreon.com/WeeklyDartscast Thank you to our Patreon members: Phil Moss, Gordon Skinner, Connor Ellis, Dan Hutchinson

you

counter strike IEM Krakow 2026 -Video Spotify Exclusive

In this Here We Go episode of Tent Talk, Nancy records from Krakow, Poland as she enters a strong season of travel and prepares to open Oxford in Europe and the British Isles. With a sober awareness of what is at stake in this hour of history, she reflects on the inner press of sonship—how true maturity is not driven by personal ambition but compelled from within by the life of Christ. She speaks to faithfulness in obscurity, long-range obedience, and the willingness to quietly proceed when no one is watching, trusting that God is forming sons for the future. Nancy challenges listeners to reconsider how they respond when more is required of them. Drawing from Hebrews 12, she explores the difference between discipline and rejection, exposure and shame, and freedom versus preserved immaturity. Rather than resisting correction or deeper formation, she invites us to see God's discipline as proof of divine ownership and love. With so much at stake, this episode calls us to yield fully, mature deeply, and allow the Father to prepare us for the days ahead. Thanks for Listening! Nancy McCready Ministries is committed to building cultures of personal and corporate discipleship so that believers can walk in maturity and their destiny with the Father. We hope this conversation today has helped you along your journey. JOIN THE CONVERSATION Every journey begins with a conversation, so we would like to invite you to join us on social media to get started! Facebook: www.facebook.com/nbmccready Instagram: www.instagram.com/nbmccready/ YouTube: www.youtube.com/@nancymccreadyministries LINKS Want to host or attend Cross Encounter? Click here: nancymccready.com/crossencounter/ Shop to Support NMM: nancymccready.com/shop/

We heard stories of physicians practicing in the USA in a specialty different from the ones they originally trained in, perhaps even from a different country. In this episode, Dr. Czarnkowski shared with us about his journey of how he first got interested in medicine, then gynecological oncology, and finally to psychiatry as well as his insights and hopes for the field of psychiatry. Trigger Warning: suicideDr. Czarnkowski (Tscharnkoffsky), is an Affiliate Associate Professor of Psychiatry at Loyola University Chicago Stritch School of Medicine and an Attending Psychiatrist at the Edward Hines Jr. VA Hospital, where he also serves as Director of Emergency Psychiatry Services and provides care in the Acute Recovery Clinic and outpatient mental health. He previously held faculty and consultation-liaison roles at the University of Illinois at Chicago and served at Advocate Christ Medical Center, including leadership of CL and Acute Inpatient Psychiatry services.Dr. Czarnkowski earned his medical degree from Jagiellonian University Medical College in Krakow, completed postgraduate training in gynecological oncology in Poland and the UK, and completed psychiatry residency at the University of Illinois at Chicago. He is board certified in General Psychiatry and Consultation-Liaison Psychiatry. He's clinician-educator, he teaches key residency curricula, supervises trainees and medical students across emergency and outpatient settings, and has received multiple institutional awards for teaching excellence including Dept. of Psychiatry Chairman's Award for Dedication in Teaching and Resident's Education and was a three time recipient of Wolf and Kettle Award.Episode produced by: Deborah ChenEpisode recording date: 12/02/2025www.medicuspodcast.com | medicuspodcast@gmail.com | Donate: http://bit.ly/MedicusDonate

｜Video Spotify Exclusive

O OVERTIME 180 discorre sobre a IEM Krakow 2026 com o vice da FURIA contra a Vitality. Porém, não há tempo para choro, a PGL Cluj-Napoca já chega no próximo sábado com paiN e FURIA na disputa.

Right after IEM Krakow 2026 grand final, we went live to discuss the playoff bracket (with the grand final specifically) to see how the results affect the standing of Vitality, FURIA, Spirit, MOUZ, and more, with the impressions from the new event location. ➡️ Follow us for updates: https://twitter.com/HLTVconfirmed

｜Video Spotify Exclusive

IEM Krakow 2026 - Day 1 - Stream B

IEM Krakow 2026 - Day 1 - Stream A part 2

IEM Krakow reaches playoffs: group stage impressions with takes on BCgame, Astralis, Aurora, FURIA, Falcons, and more in this episode of HLTV Confirmed!➡️ Follow us for updates: https://twitter.com/HLTVconfirmed

IEM Krakow 2026 - Day 1 - Stream A

(00:00) - Sähkön hinta, natun uunituore hiiri(05:05) - CSLANS.com ja Tier 2 LAN-mania(15:00) - IEM Krakova(16:00) - NIP, Legacy (+arT??)(23:00) - FUT ihastuttaa(30:00) - Onko FURIA mestariehdokas?(35:00) - NAVI = meh?(39:00) - Astralis (42:30) - Onko PARIVISION fraud? (44:30) - BCGAMEn epätiimiys(51:00) - Falcons pelkää voittamista(55:50) - FaZe :D(01:00:30) - Playoffit(01:03:20) - Anubis on...(01:06:30) - VP penkittää Perfecton(1:08:50) - Maajoukkueturnaus CS:ään?YOUTUBE: https://www.youtube.com/@natujaRobuTsekkaa meidän TikTok-tili: https://www.tiktok.com/@natujarobuLiity keskusteluun muiden cs-fanien kanssa: https://discord.gg/XxEcdhP38xhttps://twitter.com/natuhttps://www.instagram.com/natucsgo/https://twitter.com/RobuJohnsonhttps://www.instagram.com/robujohnson/

Guest: Judy Dempsey. Dempsey analyzes the stalemated Ukraine conflict, noting European refusal to accept Russianvictory, while discussing rising tensions and internal political divisions within Iran.1895 KRAKOW

TECH CLUBBERS PODCAST W/ SABINE HOFFMANN Sabine grew up in Berlin. Her first years of life she spend in East Berlin. Early 2000's She discovered her passion for spinning vinyl, when she was first exposed to electronic music. She plays a deep blend of techno and house music in all their different genres. Besides club music, she is also available for Ambient sets. But regardless of the style, you will always find Sabine playing vinyl only sets as she prefers the warmth of analog sounds and the classic feel of turntables. She has played at almost all the leading clubs in Berlin such as About Blank, Tresor, Heideglühen, Salon zur wilden Renate, Berghain Kantine, Suicide, Griessmühle, IPSE, Farbfernseher, Golden Gate, Arena Club and the list goes on. Her international profile has been steadily increasing, she already played in Tiflis, Paris, Baku, Yerevan, Krakow and Thessaloniki to name a few. Since 2016 Sabine works at the well known OYE record shop in Berlin. She is taking care of all OYE club events and also all Instores happening at one of the record shops. Since January 2023 she is hosting the OYE Podcast series. Sabine is the founder of "Frauengedeck". It´s an event series focusing on an all female line up. She wants to support and present female DJs. She has held many events at different clubs throughout Berlin like Wilde Renate, Griessmühle, Farbfernseher and Beate Uwe. The first international events outside of Germany, were held in Armenia, Azerbaijan and Georgia. Her newest project is "Dub Nation". An event series brought to life by good old colleagues and friends Sabine Hoffmann and Kenneth Christiansen. Both share the unconditional love for the deeper and more dubby side of Techno and House. She finished her Audio Engineering studies at SAE. Inspired by her gained knowledge, she started putting her focus on music production. The first result, a collaboration with No Mad Ronin is available on the label Zaijenroots. TRACKLIST: Psi Performer (Anthony Rother) ‎- 1948 [Kanzleramt] Jeff Mills - The Deep [Purpose Maker] Oliver Ho - The Link (1999) [Blueprint] Johannes Heil - 20.000 Leagues Under The Skin Pt. 2.1 [Kanzleramt] Joey Beltram - 5.7 Litre [Tresor] Surgeon - Floorshow Part 2. [Counterbalance] James Ruskin - Surfaced [Tresor] Deetron - Cone [Music Man Records] Technasia - Hydra [Technasia] Aural Emote (Ben Sims) - Theoretical [Tresor] The Horrorist - The Virus ( Ben Sims Remix ) [A45 Music] Ken Ishii - Extra ( Luke Slater Remix ) [R & S Records] Marco Bailey - The Ctila [Primate Recordings] Player - Respect Yourself [Player] Follow SABINE HOFFMANN here: Facebook: https://www.facebook.com/DjSabineHoffmann Instagram: https://www.instagram.com/sabine_hoffmann Soundcloud: https://soundcloud.com/sabine-hoffmann

From Davos to Krakow, a wide ranging conversation with @LarryTaunton on what shifted at the World Economic Forum, why Trump's message landed so hard, and what it says about globalism, elites, and ordinary people. TIMESTAMPS(0:00) Intro(0:26) Larry Taunton Joins(4:02) Did Trump Shake Davos?(5:23) Schwab Out, Larry Fink In(9:22) Davos Feels Like Twilight Zone?(15:21) Dollar Warning And Physical Gold(20:09) What Drives Trump To Fight?

Pablito has more than 100 daygame lays as a man in his 40s. But to get there he had to deal with many challenges.Daygaming in masks during covid; Starting to get consistent results instead of just getting lucky here or there; Adjusting to daygame in big cities after learning in a small beach town; Learning to get meet women on short daygame trips to Warsaw, Krakow, Belgrade, Madrid, etc.; Experimenting with open relationships; Finding a style of daygame that's more respectful towards women he's dating.In this podcast episode he tells how he did all of it.Daygame Coaching - ⁠⁠⁠https://www.strobert.blog/daygame-coaching/?utm_source=PC⁠⁠⁠⁠Free Texting, Dating & Daygame Courses - ⁠⁠⁠⁠⁠https://www.daygamecourses.com/?utm_source=PC

O OVERTIME 179 chega para falar sobre o título do MIBR no Circuit X em Curitiba, além de abordar o tema IEM Krakow 2026. Três equipes brasileiras na disputa, poderemos sair com o título?

Larry Alex Taunton on Trump's Impact at the World Economic Forum In this episode of 'Ideas Have Consequences,' Larry Alex Taunton reports from Krakow, Poland, after attending the World Economic Forum in Davos, Switzerland. Taunton discusses Donald Trump's key speech at the WEF, emphasizing Trump's focus on the American citizen and critiquing media misrepresentations of his address. He highlights Trump's plain-speaking approach, practical solutions, and the context of his statements on NATO, Greenland, and Ukraine. The episode also covers the absence of Klaus Schwab, the agenda of the World Economic Forum, and the potential dangers and allure of artificial intelligence as discussed at the event. Taunton concludes with reflections on the overall ethos of the WEF and what he learned from his conversations and observations. give me packaging for above. 

Surprising BLAST victory by PARIVISION, ahother Falcons top 2 finish, NiKo MVP explained, Vitality & Spirit losses analyzed, new Anubis takes, IEM Krakow preview with teams ranked, and more in this episode of Confirmed!➡️ Follow us for updates: https://twitter.com/HLTVconfirmed

Send us a textIn our last episode after rescuing Queen Cerulean, Chief Magician Carl attacked Captain Flashman, Eve and Dr Commander, Dr Krakow using a Dissolvo Ray Gun. Trapped in their room, their only escape was through a window that overlooking a steep cliff. To stay meant certain death but in leaving, they'd have to abandon their friend Captain Credo. Will Captain Flashman and his friends survive their descent down the crack? Or will Carl melt the door to their sanctuary and destroy them with a blast from the Dissolvo Ray Gun? And what will happen to Captain Credo now that's he's been abandoned by his friends? Episode Website: https://captainflashmandefenderoftheuniverse.buzzsprout.comTo keep up to date on all Captain Flashman news, follow him on Facebook and Instagram.This episode stars:Melyssa Ade as Little Chester, Corporal Earl, and VulkarenGene Abella as the Soldier with Gardening InterestsSam Agro as Chief Magician Carl and the AnnouncerSean Browning as Captain FlashmanDave Healey as Khan The CruelVicki jenkins as Dr Krakow and Princess HaloJane Luk as Queen Cerulean & TanyaAnn McDougall as EveBrian Webber as The FreemanMusic by Jeff RosenthalProduced, Directed and Written by Dave HealeyAssociate Producer Vicki Jenkins Episode Recorded, Mixed and Soundscape Design by Dave HealeyIntro and Outro Designed by Dave Healey and Dylan Shropshire and Mixed by Dylan Shropshire.© Dave Healey 2025Support the showCaptain Flashman Fighting Evil Since 2023

Krakow .  Welcome back to the  Dr. Mary Travelbest Guide podcast. A few weeks ago, I returned from a 90-day journey around the world, and I'm excited to connect with fellow travelers and share experiences.   Today, we will discuss Krakow, Poland, and when to admit you are not ready for a trip. We will discuss passports and then my travel mistakes. Get ready now, as we are starting.   The FAQ is:  Marcia, who recently returned from a solo trip to Antarctica, asked: "At what point does a destination become a bad match for my solo senior travel — and how do I admit that early?"    Answer: I emphasize empowerment. I permit you to change course, leave early, or say "this isn't for me" without framing it as failure. A destination isn't "wrong" because it challenges you — but it is wrong if it consistently drains your energy, confidence, or sense of safety. If you find yourself constantly anxious, overly fatigued, or forcing yourself to "push through," just listen to your mind or body. Changing plans, leaving early, or choosing a different destination next time is not failure — it's wisdom. The goal of solo travel isn't endurance; it's fulfillment. And knowing when to pivot is one of the strongest travel skills you can develop. In Amsterdam, I had to change my destination frequently, which was challenging, but I managed to do so. One day, when I had some flexibility in my schedule, I scheduled a massage. I searched for "massage near me" and was delighted with the results. Sometimes that's all it takes for a new perspective.   60-second confidence challenge Your challenge today is to check your passport. That's right, take it out and open it up.   Do you have at least six months left on your passport? If not, you need to renew it.   If you like today's Confidence Challenge, my book series delves deeper into passport documents and solo travel for women. You can find the series at the link in the description.    See Book A for addressing this concern..  Find it on the website​​ at https://www.5stepstosolotravel.com/ or on Amazon. It's a multiple-part series. Today's special destination is Krakow, Poland   First, I'll talk about the things to see as a tourist, and then I'll share some 'off the regular' tourist ideas for you. It's interesting to learn that Poland is roughly the size of Texas. Historical tensions persist among Polish communities in neighboring Kazakhstan, Russia, and Germany. I've also heard about soldiers being sent from Siberia to Ukraine. The country underwent a significant change in 1989 when the Solidarity movement overthrew the socialist government. I reflected on the historical gravity of Auschwitz, where many lives were lost. Kraków, Poland, is one of Europe's most enchanting cities, renowned for its history, charm, and culture. Kraków offers a welcoming mix of walkable streets, accessible attractions, and heartfelt hospitality. Let's Explore the Old Town and Wawel Hill https://krakow.travel/en/55-krakow-main-market-square Start your morning in Rynek Główny, the Main Market Square — one of the largest medieval squares in Europe. It's mostly flat with smooth pathways, though some cobblestones can be tricky; use a slower pace or roll along the outer edges, which are more level, for those with mobility issues. In the center stands the Cloth Hall, filled with stalls selling amber jewelry, handmade crafts, and souvenirs. Elevators are available to reach the upper gallery, which houses the 19th-century Polish Art Museum. Nearby, the St. Mary's Basilica is famous for its hourly trumpet call from the tower. Inside, ramps and wide aisles make it accessible for most visitors. https://mariacki.com/en/   https://visitkrakow.com/kazimierz/   https://visitkrakow.com/guide-to-oskar-schindlers-enamel-factory-museum/     https://www.catholicapostolatecenter.org/blog/st-faustina-and-the-catholic-heritage-of-poland?   Travel Mistake to Avoid in Kraków included Eurail reservations.     Connect with Dr. Travelbest 5 Steps to Solo Travel website Dr. Mary Travelbest X Dr. Mary Travelbest Facebook Page Dr. Mary Travelbest Facebook Group Dr. Mary Travelbest Instagram Dr. Mary Travelbest Podcast Dr. Travelbest on TikTok Dr.Travelbest on YouTube In the news  

Can u travel before Shabbat!?Famous story from krakow !Can we get married on Shabbat!?What's more חשוב milk or meat!?

Listen now to Aaron's story about his journey to the Auschwitz death camp. Through your donations, Israel Team provided transportation, food, and lodging for a group of students and faculty to travel from Prague in the Czech Republic to Krakow, Poland for three days to tour Auschwitz, Birkenau, and Oscar Schindler's enamel works factory in which he saved the lives of over 1,200 Jewish people.

Sundance feature programmer Ania Trzebiatowska joins the show to talk about curation as craft, responsibility, and intuition. From her roots in Poland to running Krakow's Off Camera festival, working in acquisitions at Visit Films, and programming U.S. and world documentary features at Sundance, Ania reflects on how taste is formed and why being pleasantly surprised when viewing submissions still matters most.We discuss the realities filmmakers obsess over, including who you know, timing, marketplace “success,” and why Vimeo analytics do not tell the full story. Ania breaks down what actually happens behind the scenes at Sundance, how programmers balance limited slots with thousands of film submissions, and why being the right fit matters more than trends or agendas.She shares why festivals need balance between urgent, heavy films and work that is entertaining, humane, and emotionally alive. Drawing from examples like André Is an Idiot and Gleason, Ania explains how character-driven storytelling can carry even the most difficult subjects. Advice to filmmakers: do your research, be clear about what you are making, and remember that programmers are rooting for you, even when the answer might still be no.What Movies Are You Watching? Listen to all episodes on Spotify, Apple Podcasts, and more, as well as at www.pastpresentfeature.com. Like, subscribe, and follow us on our socials @pastpresentfeature The Past Present Feature Film Festival - Nov. 20-22, 2026 in Hollywood, CA - Submit at filmfreeway.com/PastPresentFeature

Tuesday of the Fourth Week of Advent Optional Memorial of St. John of Kanty, 1390-1473; he was ordained a priest and became a professor of theology at the University of Krakow, Poland; he was sent to be a parish priest, but later returned to Krakow to teach scripture for the rest of his life; he was a serious, humble man, known to all of the poor of Krakow for his kindness; he made a pilgrimage to Jerusalem, hoping to be martyred by the Turks; he made four subsequent pilgrimages to Rome, carrying his luggage on his back; when warned to watch over his health, he remarked that, for all of their austerity, the fathers of the desert lived long lives Office of Readings and Morning Prayer for 12/23/25 Gospel: Luke 1:57-66

Send us a textIn our last episode, Captain Flashman, Dr Commander, Dr Krakow and Eve drugged Queen Cerulean with Forgetium, the drug of forgetfulness. With the Queen under their control, they reviewed her troops in the hopes of using them against their enemy, Chief Magician Carl. In the meantime, Carl and his assistant, Corporal Earl made plans to assassinate Captain Flashman as he was reviewing Queen Cerulean's troops. Will Carl succeed in his nefarious plan? Or will Carl get his comeuppance once again? Episode Website: https://captainflashmandefenderoftheuniverse.buzzsprout.comTo keep up to date on all Captain Flashman news, follow him on Facebook and Instagram.This episode stars:Melyssa Ade as Corporal EarlGene Abella as Captain CredoSam Agro as Chief Magician Carl and the AnnouncerSean Browning as Captain FlashmanDave Healey as the Stuffed-Up Sponsor, Guard 1 & Squeaky Toy GuardVicki Jenkins as Dr KrakowJane Luk as Queen Cerulean & the Program SellerAnn McDougall as EveMusic by Jeff RosenthalProduced, Directed and Written by Dave HealeyAssociate Producer Vicki Jenkins Episode Recorded, Mixed and Soundscape Design by Dave HealeyIntro and Outro Designed by Dave Healey and Dylan Shropshire and Mixed by Dylan Shropshire.© Dave Healey 2025Support the showCaptain Flashman Fighting Evil Since 2023

Gary Gwadera is the solo project of Piotr Gwadera—a composer, improviser, drummer and anthropologist-dreamer from the city of Łódź, Poland. In 2024, he released the critically acclaimed album “Far, Far in Chicago. Footberk Suite” an imaginary musical journey through time and space, where Polish traditional dance, oberek, and Chicago footwork find common ground in dynamic, triple rhythms. This year, at the Unsound Festival in Osaka, Krakow, and New York, his dream came true when he played with footwork pioneer RP Boo, one of Chicago's most legendary figures. This hour-long mix features their performance “Another Brain, The Birth of Footberk” (the title refers to one of the scenes from the legendary “Frankenstein” (1931), which, in RP Boo's opinion, stylistically corresponds to the music of the Polish village, played in the U.S. by folk bands of the Polish diaspora), which took place on October 30, 2025, during the Unsound Festival at the Lincoln Center in New York. The live set is bookended by an oberek from the Opoczno region, played by Władysław Koperkiewicz's band. Gary Gwadera is an artist of the SHAPE+ platform for innovative music and interdisciplinary art, co-funded by the EU and Pro Helvetia. Tracklist: RP Boo & Gary Gwadera – Another Brain RP Boo & Gary Gwadera – Laboratory RP Boo & Gary Gwadera – Heavy Heat Gary Gwadera – Chicago RP Boo & Gary Gwadera – The Birth of Footberk Gary Gwadera – Battle (“kasowanie”) RP Boo & Gary Gwadera – Total Darkness Gary Gwadera – Dwapotrzy RP Boo & Gary Gwadera – Eraser RP Boo & Gary Gwadera – 02-52-03 Gary Gwadera & RP Boo – Goodbye, Charlie! RP Boo & Gary Gwadera – As stupid as a calf

JCO Editor-in-Chief Dr. Jonathan Friedberg is joined by colleagues Dr. Jennifer Woyach, Dr. Wojciech Jurczak, and Dr. Matthew Davids to discuss simultaneous publications presented at ASH 2025 on pertibrutinib, a new upfront treatment option for patients with chronic lymphocytic leukemia. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Jonathan Friedberg: I'm Jonathan Friedberg, editor of Journal of Clinical Oncology, and welcome to JCO After Hours, where we are covering two manuscripts that were presented at the American Society of Hematology meeting 2025 in Orlando, Florida. I am delighted to be joined by colleagues on this call to discuss these pivotal manuscripts which cover the topic of pirtobrutinib, a new upfront treatment option for patients with chronic lymphocytic leukemia. I will first just introduce our guests, Dr. Woyach. Dr. Jennifer Woyach: Hi, my name is Jennifer Woyach. I am from the Ohio State University. Dr. Wojciech Jurczak: Hello, I am Wojciech Jurczak, working at the National Research Institute of Oncology in Krakow, Poland. Dr. Matthew Davids: Hi, I am Matthew Davids from Dana-Farber Cancer Institute in Boston. Dr. Jonathan Friedberg: We are going to start by just learning a little bit about these two trials that were both large, randomized phase 3 studies that I think answered some definitive questions. We will start with your study, Jennifer. If you could just describe the design of your study and the patient population. Dr. Jennifer Woyach: Absolutely. So this is the BRUIN CLL-314 study, and this is a phase 3 randomized trial of pirtobrutinib versus ibrutinib in patients with CLL or SLL who had not previously been treated with a covalent BTK inhibitor. The patients were both treatment-naive and relapsed/refractory, about one-third of the patients treatment-naive, the rest relapsed/refractory, and they were stratified based upon 17p deletion and the number of prior lines of therapy. The primary objective was looking at non-inferiority of overall response rate over the entire treated population as well as the relapsed/refractory patient population. Key secondary objectives included progression-free survival in the intention-to-treat and the smaller relapsed/refractory and treatment-naive populations. Dr. Jonathan Friedberg: And just comment a little bit on the risk of the patients. Dr. Jennifer Woyach: This study was fairly typical of this cohort of patients. Within the relapsed/refractory patient population, there was a median of one prior line of therapy in each of the groups, up to nine prior lines of therapy in the patients included on the study. For the overall cohort, about two-thirds of the patients were IGHV unmutated, about 15% had 17p deletion, 30% had TP53 mutations, and about 35% to 40% had a complex karyotype, which is three or more abnormalities. Dr. Jonathan Friedberg: And what were your findings? Dr. Jennifer Woyach: Regarding the primary outcome, which is the focus of the publication, we did find that pirtobrutinib was indeed non-inferior and actually superior to ibrutinib for overall response rate throughout the entire patient population and in both the relapsed/refractory and treatment-naive cohorts. PFS is a little bit immature at this time but is trending towards also being significantly better in pirtobrutinib-treated patients compared with ibrutinib-treated patients. Probably most significantly, we found this to be the case in the treatment-naive cohort where there was a striking trend to an advantage of pirtobrutinib versus ibrutinib. Dr. Jonathan Friedberg: And the follow-up that you have on that progression-free survival? Dr. Jennifer Woyach: So we have about 18 months follow-up on progression-free survival. Dr. Jonathan Friedberg: The second study, Wojciech, can you just go through the design and patient population that you treated? Dr. Wojciech Jurczak: Thank you, Dr. Friedberg, for this question. So the BRUIN CLL-313 study was, in fact, the first phase 3 study with pirtobrutinib in exclusively untreated CLL patients. It was a randomized study where we challenged pirtobrutinib versus bendamustine-rituximab. At the time we designed the protocol, bendamustine-rituximab was an option as a standard of care, and Bruton tyrosine kinase monotherapy was used far more commonly than nowadays. The primary target of the study was progression-free survival. We took all untreated patients except for those with 17p deletions. Therefore, it is a good representation for intermediate risk. We had about 60% of the population, 56 to be precise, which was unmutated, evenly distributed into two treatment arms. 17p deleted cases were excluded, but we had about 7% and 8% of TP53 mutated patients as well as about 11% and 7%, respectively, in the pirtobrutinib and bendamustine-rituximab arm of patients with complex karyotype. The progression-free survival was in favor of pirtobrutinib and was assessed by an independent review committee. What is important is that the progression-free survival of the bendamustine-rituximab arm was actually similar to the other studies addressing the same questions, like the comparison with ibrutinib in the ALLIANCE study or zanubrutinib in the SEQUOIA study. What was different was the hazard ratio. In our study, it was 0.20. It was one of the longest effect sizes noted in the frontline BTK study. It represented an 80% reduction in progression-free survival or death. If we compare it to ibrutinib or zanubrutinib, it was 0.39 and 0.42 respectively. Presumably, this great effect contributed towards a trend of overall survival difference. Although survival data are not mature enough, there is a clear trend represented by three patients we lost in the pirtobrutinib arm versus 10 patients lost in the bendamustine-rituximab arm. This trend in overall survival is becoming statistically significant despite the fact that there was a possibility of crossover, and effectively 52.9 patients, which means 18 out of 34 patients relapsing in the bendamustine-rituximab arm, were treated by pirtobrutinib. Dr. Jonathan Friedberg: I am going to turn it over to Matt. The question is: why study pirtobrutinib in this patient population? And then with these two studies, how do you find the patients that were treated, are they representative of people who you see? And do you see this maybe being approved and more widely available? Dr. Matthew Davids: I think in terms of the first question, why study this in a frontline population, we have seen very impressive data with pirtobrutinib in a very difficult-to-treat population of CLL patients. This was from the original BRUIN phase 1/2 study where most of the patients had at least two or three lines of therapy, often both a covalent BTK inhibitor and the BCL2 inhibitor venetoclax, and yet they were still responding to pirtobrutinib. The drug was also very well tolerated in that early phase experience. And actually, we have seen phase 3 data from the BRUIN 321 study comparing pirtobrutinib to bendamustine and rituximab in a relapse population as well. So I think that really motivated these studies to look at pirtobrutinib as a first therapy. You know, often in other cancers of course, we want to use our best therapy first, and I think these studies are an initial step at looking at that. In terms of the second question around the patient population, these are pretty representative patient populations, I would say, for most frontline CLL studies. We see patients who are a bit younger and fitter than sort of the general population of CLL patients who are treated in clinical practice, and I think that is true here as well. Median age in the sort of mid-60s here is a bit younger than the typical patients we are treating in practice. But that is not different from other CLL frontline studies that we have seen recently, so I think it makes it a little bit easier as we kind of think across studies to feel comfortable that these are relatively similar populations. Dr. Jonathan Friedberg: How do you see this either getting regulatory approval or potentially being used compared to current standard of care options? Dr. Matthew Davids: So my understanding is that both of these trials were designed with registrational intent in the frontline setting, and they are both positive studies. That is certainly very encouraging in terms of the potential for an approval here. We have seen in terms of the FDA recently some concerns around the proportion of patients who are coming from North America, and my understanding is that is relatively low on these two studies. But nonetheless, the datasets are very impressive, and so I think it is certainly supportive of regulatory approval for frontline pirtobrutinib. Dr. Jonathan Friedberg: I will ask Jennifer a question. The control arm in your study was ibrutinib, and I think many in the audience may recognize that newer, second-generation BTK inhibitors like acalabrutinib and zanubrutinib are more frequently used now if monotherapy is decided. How do you respond to that, and how would you put your results in your pirtobrutinib arm in context with what has been observed with those agents? Dr. Jennifer Woyach: Yeah, that is a great question. Even though in the United States we are predominantly using acalabrutinib or zanubrutinib when choosing a monotherapy BTK inhibitor, this is actually not the case throughout the entire world where ibrutinib is still used very frequently. The head-to-head studies of both acalabrutinib and zanubrutinib compared to ibrutinib have shown us pretty well what the safety profile and efficacy profile of the second-generation BTK inhibitors is. So even though we do not have a head-to-head study of acalabrutinib or zanubrutinib versus pirtobrutinib, I think, given the entirety of data that we have with all of the covalent BTK inhibitors, I think we can safely look at the pirtobrutinib arm here, how the ibrutinib arm compares or performs in context with those other clinical trials. And though we really can not say anything about pirtobrutinib versus acalabrutinib or zanubrutinib, I think we can still get a good idea of what might be the clinical scenarios in which you might want to choose pirtobrutinib. Dr. Jonathan Friedberg: And Wojciech, do you agree with that? Obviously, I think you have acknowledged that chemoimmunotherapy is rarely used anymore as part of upfront treatment for CLL. So, I guess a similar question. If you were to put the pirtobrutinib result in your study in context with, I guess, more contemporary type controls, would you agree that it is competitive? Dr. Wojciech Jurczak: Well, I think that that was the last study ever where bendamustine-rituximab was used as a comparator arm. So we should notice that smashing difference. Because if we look at the progression-free survival at two years, we have 93.4% in pirtobrutinib arm versus 70.7% in bendamustine-rituximab arm. Bendamustine-rituximab arm did the same as in the other trials, like ALLIANCE or SEQUOIA. Pirtobrutinib did exceptionally well, as pirto is not just the very best BTK inhibitor overcoming the resistance, but perhaps even more important for the first line, it is very well tolerated and is a very selective drug. Now, if we look at treatment-related adverse events, the discontinuation rate, they were hardly ever seen. If we compared the adverse events in exposure-adjusted incidence, literally all adverse events were two or three times higher in bendamustine-rituximab arm except for the bleeding tendency, which however was predominantly in CTCAE grade 1 and 2 with just 0.7% of grade 3 hemorrhage. Therefore, I think that we should actually put the best and the safest drugs upfront if we may, and pirtobrutinib is, or should be, the first choice if we choose monotherapy. Now, I understand that we are not presenting you the data of pirtobrutinib in combination with anti-CD20 or with BCL2 inhibitors, but that is to come. Dr. Jonathan Friedberg: Matt, how would you envision, were regulatory approval granted and this were an option, using this in the upfront patient population? Is there anybody who you would preferentially use this or start on this treatment? Or would this be something that you would tend to reserve for second line? Dr. Matthew Davids: So I would say that in general for most of my patients who would want to start with a continuous BTK inhibitor, I would still use a covalent BTK inhibitor, and I say that for a couple of reasons despite the very promising data from these studies. The first is that the follow-up for both of these phase 3 trials is still quite short, in the range of a median 18 to 24 months. And we know that CLL is a marathon, not a sprint, and these patients are going to probably be living for a very long time. And we do have much longer follow-up from the covalent BTK inhibitors, median of 10-year follow-up with ibrutinib and five to six years with zanubrutinib and acalabrutinib respectively. And you know, I do not think that the pirtobrutinib is going to fall off a cliff after two years, but on the other hand, I think there is a lot of value to long-term data in this disease, and that is why I think for most of my patients I would stick with covalent BTK inhibitors. But the other important factor that we need to consider is patients who are younger and may have many different CLL treatments over the years. We have to be very careful, I think, about how we sequence these drugs. We know right now that we can start with covalent BTK inhibitors and then subsequently patients will respond well to the non-covalent inhibitor pirtobrutinib in later lines of therapy. But right now we do not have prospective data the other way around. So how will the patients on these studies who progress on pirtobrutinib respond to covalent BTK inhibitors? We do not know yet. There have not been a lot of progression events, which is great, but we would like to see some data in that respect to feel more comfortable with that sequence. Now, I do think that particularly for older patients and those who have significant cardiovascular comorbidities, if they wanted to go on a continuous BTK inhibitor, I do think these data really strongly support using pirtobrutinib as the BTK inhibitor of choice in that population. In particular, the cardiovascular risks with pirtobrutinib seem to be quite low. I was very struck in the comparison with BR that the rate of AFib was equivalent between the two arms of the study. And that is really the first time we have seen that with any of these BTK inhibitors, no elevated risk of AFib in a randomized study. I think that is the population where it will get the most traction first, is the upfront, sort of older patient with significant cardiovascular comorbidities. And as the data from these studies mature, I think that we will start to see more widespread use of pirtobrutinib in the frontline setting. Dr. Jonathan Friedberg: Jennifer, I am just curious if you have any personal experience or heard anecdotally about after progression on pirtobrutinib the use of other BTK inhibitors and whether there is a growing experience there. Dr. Jennifer Woyach: I do not think that there is much clinical experience, you know, as Matt alluded to, it certainly has not been tested yet. There has been some data in relapsed CLL suggesting that in people who have resistance mutations to covalent BTK inhibitors after treatment with pirtobrutinib, sometimes those mutations go away. I think most of us are concerned that they are probably not actually gone but maybe in compartments that we just have not sampled, suggesting that sort of approach where you might sequence a covalent inhibitor after a non-covalent in somebody who had already been resistant probably would not work that well. But, you know, in this setting where people had never been exposed to a covalent BTK inhibitor before, we really have no idea what the resistance patterns are going to be like. We assume they will be the same as what we have seen in relapsed CLL, but I think we just need some longer follow-up to know for sure. Dr. Wojciech Jurczak: If I may confront Dr. Davids about the use of covalent BTK inhibitors upfront, well, I think that we should abandon the idea of using the first and the second and the third generation, at least if we don't have medical lines. If we endlessly block the same pathway, it is not going to be effective. So if pirtobrutinib gets approval in first, second line, we do not necessarily have to use it in the first line. I am not here in a position to defend that we should treat patients with pirtobrutinib upfront and not BCL2 time-limited regimen. However, the way I look at CLL patients when choosing therapy is not just how should I treat them now, but what would be the best regimen in 5, 10 years if I have to re-treat them. And in some instances, the idea may be that in this setting we would like to have a BTK inhibitor upfront to have a BCL2 inhibitor later to make it time-limited. Although I understand and I agree with Matthew that if we have an elderly, fragile population, then the charm of having a drug taken once a day in a tablet with literally few cardiovascular adverse events might be an option. Dr. Jonathan Friedberg: And I will give Matt the last word whether he wants to respond to that, and also just as a forward-looking issue, I know both investigators have implied that there will be future studies looking at combinations with pirtobrutinib, and if you have any sense as to what you would be looking for there. Dr. Matthew Davids: The field really is heading toward time-limited therapy for most patients, I would say. There is a bit of a discrepancy right now in the field between sort of what we are doing in academic practice and what is done sort of more widely in community practice. And so right now we are going to see evolving datasets comparing these approaches. We are already seeing data now from the CLL17 study with ibrutinib comparing continuous to time-limited venetoclax-based therapy, and we are seeing similar efficacy benefits from these time-limited therapies without the need for continuous treatment. And so that is where I think some of the future studies with pirtobrutinib combining it with venetoclax and other partners are so important. Fortunately, several of these studies are already ongoing, including a phase 3 trial called CLL18, which is looking at pirtobrutinib with venetoclax, comparing that to venetoclax and obinutuzumab. So I am optimistic that we are going to be developing these very robust datasets where we can actually use pirtobrutinib in the frontline setting as a time-limited therapy as a component of a multi-drug regimen. So far, those early data are very promising. Dr. Wojciech Jurczak: Perhaps last but not least, in a single center we have treated over 300 patients with pirtobrutinib. So eventually some of them relapsed. And I must say that our experience on BCL2 inhibitors, not just venetoclax but including sonrotoclax, are appealingly good. Therefore, by using pirtobrutinib even earlier, we do not block the efficacy of other compounds. Dr. Jonathan Friedberg: All right. Well, I want to thank all of our speakers. I also want to congratulate our two guests who presented these very influential papers at the ASH Annual Meeting, and chose to publish them in JCO, so we thank you for that, and Dr. Davids for your commentary - really appreciated. That is this episode of JCO After Hours. Thank you for your attention. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Disclosures Dr. Wojciech Jurczak Consulting or Advisory Role: BeiGene, Lilly, Abbvie/Genentech, Takeda, Roche, AstraZeneca Research Funding: Roche, Takeda, Janssen-Cilag, BeiGene, AstraZeneca, Lilly, Abbvie/Genentech Dr. Jennifer Woyach Consulting or Advisory Role: Pharmacyclics, Janssen, AstraZeneca, Beigene, Loxo, Newave Pharmaceutical, Genentech, Abbvie, Merck Research Funding: Company name: Janssen, Schrodinger, beone, Abbvie, Merck, Loxo/Lilly Dr. Matthew Davids Honoraria: Curio Science, Aptitude Health, Bio Ascend, PlatformQ Health, Plexus Consulting or Advisory Role: Genentech, Janssen, Abbvie, AstraZeneca, Adaptive Biotechnologies, Ascentage Pharma, BeiGene, Lilly, Bristol-Myers Squibb, Genmab, Merck, MEI Pharma, Nuvalent, Inc., Galapagos NV, Schroedinger Research Funding: Ascentage Pharma, Novartis, MEI Pharma, AstraZeneca  

Was fällt ihnen bei dem Wort Weihnachtsschnitzerei ein? Das Erzgebirge, oder? Pyramiden, Krippen, Schwibbögen? Klönkist-Reporterin Heike Mayer hat Klaus Pieper kennen gelernt, der schon seit 40 Jahren Weihnachtspyramiden herstellt – nicht im Erzgebirge, sondern in seiner Werkstatt in Serrahn-Hof bei Krakow. Klaus Pieper ist in dieser Zeit ein echter Experte geworden.

PREVIEW: Rail Sabotage in Poland, Quid Bono? Guest: Gregory Copley John Batchelor speaks with Gregory Copley about the amateur sabotage of a Polish rail line, which Poland blames on Russia, with Copley asking "who benefits" (qui bono), suggesting the easily repaired incident was political and symbolic, recalling the Nord Stream 2 sabotage, initially blamed on Russia but later linked to Ukraine, heightening paranoia about the conflict. 1895 KRAKOW

November 18th, 2025:  Dedication of the Basilicas of Ss Peter & Paul;  Bl Salome of Krakow; Basilicas of Ss Peter & Paul - All Nations to Obey the Gospel; Three Kingdoms, Two Basilicas; The Good Example of Bl Salome; Basilicas of Ss Peter & Paul - Respect for God's House

The group was scheduled to have mass at the Kraków Cathedral but was last minute rescheduled to the historic church in the middle of crackle Square—St. Barbara. Fr. Steve had to readjust and didn't disappoint with tour and holy Mass at this amazing church. 

Let's Think About "Sleep Helping With PTSD" With Special Guest Barry Krakow Barry shares his thoughts on sleep helping with PTSD, reminding people that sleep is beneficial for us more than we could even imagine. While learning about Barry, we discussed his book and the importance of allowing our bodies to rest and heal from the inside out. This episode aims to prompt thought.  To stay in touch, please visit Barry's website at https://barrykrakowmd.com/ to learn more about him.

******Support the channel******Patreon: https://www.patreon.com/thedissenterPayPal: paypal.me/thedissenterPayPal Subscription 1 Dollar: https://tinyurl.com/yb3acuuyPayPal Subscription 3 Dollars: https://tinyurl.com/ybn6bg9lPayPal Subscription 5 Dollars: https://tinyurl.com/ycmr9gpzPayPal Subscription 10 Dollars: https://tinyurl.com/y9r3fc9mPayPal Subscription 20 Dollars: https://tinyurl.com/y95uvkao ******Follow me on******Website: https://www.thedissenter.net/The Dissenter Goodreads list: https://shorturl.at/7BMoBFacebook: https://www.facebook.com/thedissenteryt/Twitter: https://x.com/TheDissenterYT This show is sponsored by Enlites, Learning & Development done differently. Check the website here: http://enlites.com/ Dr. Alexander Rosenberg is the R. Taylor Cole Distinguished Professor of Philosophy at Duke University. In 2016 he was the Benjamin Meaker Visiting Professor at the University of Bristol. He has held fellowships from the National Science Foundation, the American Council of Learned Societies, and the John Simon Guggenheim Foundation. In 1993, Dr. Rosenberg received the Lakatos Award in the philosophy of science. In 2006-2007 he held a fellowship at the National Humanities Center. He's the author of both fictional and non-fictional literature, including The Atheist's Guide to Reality, The Girl from Krakow, How History Gets Things Wrong, and Blunt Instrument: Why Economic Theory Can't Get Any Better...Why We Need It Anyway. In this episode, we focus on Blunt Instrument. We start by discussing why we need to know about economic theory, whether economics is a science, and how it is theory-driven. We also discuss whether Homo economicus exists, explanation and prediction in economics, and whether it is ideology-driven. We talk about game theory, why we can't do without economic theory, and institution design. Finally, we discuss economics and political activism.--A HUGE THANK YOU TO MY PATRONS/SUPPORTERS: PER HELGE LARSEN, JERRY MULLER, BERNARDO SEIXAS, ADAM KESSEL, MATTHEW WHITINGBIRD, ARNAUD WOLFF, TIM HOLLOSY, HENRIK AHLENIUS, ROBERT WINDHAGER, RUI INACIO, ZOOP, MARCO NEVES, COLIN HOLBROOK, PHIL KAVANAGH, SAMUEL ANDREEFF, FRANCIS FORDE, TIAGO NUNES, FERGAL CUSSEN, HAL HERZOG, NUNO MACHADO, JONATHAN LEIBRANT, JOÃO LINHARES, STANTON T, SAMUEL CORREA, ERIK HAINES, MARK SMITH, JOÃO EIRA, TOM HUMMEL, SARDUS FRANCE, DAVID SLOAN WILSON, YACILA DEZA-ARAUJO, ROMAIN ROCH, YANICK PUNTER, CHARLOTTE BLEASE, NICOLE BARBARO, ADAM HUNT, PAWEL OSTASZEWSKI, NELLEKE BAK, GUY MADISON, GARY G HELLMANN, SAIMA AFZAL, ADRIAN JAEGGI, PAULO TOLENTINO, JOÃO BARBOSA, JULIAN PRICE, HEDIN BRØNNER, FRANCA BORTOLOTTI, GABRIEL PONS CORTÈS, URSULA LITZCKE, SCOTT, ZACHARY FISH, TIM DUFFY, SUNNY SMITH, JON WISMAN, WILLIAM BUCKNER, LUKE GLOWACKI, GEORGIOS THEOPHANOUS, CHRIS WILLIAMSON, PETER WOLOSZYN, DAVID WILLIAMS, DIOGO COSTA, ALEX CHAU, CORALIE CHEVALLIER, BANGALORE ATHEISTS, LARRY D. LEE JR., OLD HERRINGBONE, MICHAEL BAILEY, DAN SPERBER, ROBERT GRESSIS, JEFF MCMAHAN, JAKE ZUEHL, MARK CAMPBELL, TOMAS DAUBNER, LUKE NISSEN, KIMBERLY JOHNSON, JESSICA NOWICKI, LINDA BRANDIN, VALENTIN STEINMANN, ALEXANDER HUBBARD, BR, JONAS HERTNER, URSULA GOODENOUGH, DAVID PINSOF, SEAN NELSON, MIKE LAVIGNE, JOS KNECHT, LUCY, MANVIR SINGH, PETRA WEIMANN, CAROLA FEEST, MAURO JÚNIOR, 航 豊川, TONY BARRETT, NIKOLAI VISHNEVSKY, STEVEN GANGESTAD, TED FARRIS, HUGO B., JAMES, JORDAN MANSFIELD, CHARLOTTE ALLEN, PETER STOYKO, DAVID TONNER, LEE BECK, PATRICK DALTON-HOLMES, NICK KRASNEY, RACHEL ZAK, AND DENNIS XAVIER!A SPECIAL THANKS TO MY PRODUCERS, YZAR WEHBE, JIM FRANK, ŁUKASZ STAFINIAK, TOM VANEGDOM, BERNARD HUGUENEY, CURTIS DIXON, BENEDIKT MUELLER, THOMAS TRUMBLE, KATHRINE AND PATRICK TOBIN, JONCARLO MONTENEGRO, NICK GOLDEN, CHRISTINE GLASS, IGOR NIKIFOROVSKI, AND PER KRAULIS!AND TO MY EXECUTIVE PRODUCERS, MATTHEW LAVENDER, SERGIU CODREANU, AND GREGORY HASTINGS!

Bu bölümde Xbox Game Pass zammı, OpenAI'ın Sora uygulaması, Mert'in Krakow gezisi ve One Battle After Another filmi üzerine sohbet ettik.Bizi dinlemekten keyif alıyorsanız, kahve ısmarlayarak bizi destekleyebilir ve Telegram grubumuza katılabilirsiniz. :)Yorumlarınızı, sorularınızı ya da sponsorluk tekliflerinizi info@farklidusun.net e-posta adresine iletebilirsiniz.Zaman damgaları:00:00 - Kıbrıs02:26 - Krakow22:50 - Sora 21:10:40 - Tim Cook'un emekliliği1:24:08 - iOS Bootcamp1:32:42 - Okuduklarımız1:49:26 - İzlediklerimiz, One Battle After Another2:08:18 - Xbox Game Pass Zammı2:41:08 - EA satıldı2:51:08 - Haftanın albüm tavsiyeleriBölüm linkleri:MonoforPierogiKvassKrakow SimitiWawel DragonSora 2 is heresomeone should go to jail for thisAI Slop Is Destroying The InternetSora 2 clones start flooding the App Store worldwideSora, AI Bicycles, and Meta DisruptionOpenAI's computing deals top $1tnAI startup Anthropic agrees to pay $1.5bn to settle book piracy lawsuitConnectionsHow people are using ChatGPTMeta will soon use your AI chats to personalize your feedsThe head of ChatGPT won't rule out adding adsParazit: Böcekleştiren Kapitalizm / Emrah Safa Gürkan - Opus Magnum 52Apple's Next CEO IdentifiedApple sidelines lighter Vision Pro to prioritize smart glassesBenjamin Button Reviews macOSStatus and CultureMaterial WorldThe Lost BusOne Battle After AnotherSlow HorsesList of highest-paid film actorsThere Will Be BloodDisney Plus is getting another price hikeMicrosoft revamps Xbox Game Pass plans and hikes Ultimate to $29.99 a monthCDKeys$55 billion EA buyout hands Madden over to investors including Saudi Arabia and Jared KushnerMammal Hands

Michelle St. John is the founder and director of VinE (Veganism in Education). VinE aims, through education, to encourage the development of empathy, critical thinking and ethical decision making, She has background in law, having worked as a Crown Prosecutor, a Magistrate and as guest lecturer on English Law at the Jagiellonian University, Krakow.Heather Marshall is a Senior Lecturer and Religious Education PGCE Course Leader at  Edge Hill University . She is a specialist in #religiouseducation pedagogy but also has interests spanning diversity in learning environments, the impact of digital technologies on teaching, teacher identity formation, education policy, and effective assessment strategies. She is a VinE ambassador.In Sentientist Conversations we talk about the most important questions: “what's real?”, “who matters?” and "how can we make a better world?"Sentientism answers those questions with "evidence, reason & compassion for all sentient beings." The video of our conversation is ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠here on YouTube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.00:00 Clips00:53 Welcome03:00 Heather's Intro- Teaching kids, now teaching teachers and research- Richard Twine episode04:11 Michelle's Intros- Polish & English parents- Social anthropology- Law (barrister and magistrate), human rights and justice- Vegan at 50 "that was the big change... human rights, animal rights, hand in hand"- "Education was a key for change... because in my owneducation I hadn't been given that opportunity to explore the moral status of animals"- Marc Bekoff, Melanie Joy episodes- Founding VinE "This is where we begin"- Launching resources with Angela Hill from RE Today  ⁨@re-today-services⁩  - Ethical veganism as a worldview (featuring religious andnon-religious ways in like #Sentientism)- Spirited arts competition with the @animalinterfaithalliance- Partnering with The Vegan Organic Network@GrowingGreenVideos 07:53 What's Real?Heather- Not brought up spiritual but a deep interest in religion and society- "I've got quite a secular worldview... but I understand the importance of religion... the impact... why people might want to be involved in that"- Critical thinking & questioning "I am quite scientific"- As a social scientist "I do recognise that things are beyond the physical as well"- Interested in psychology and how the brain works- Not so concerned about the metaphysical e.g. "whathappens after death"- "That probably seems a bit weird for someone that teaches RE (Religious Education)... I'm interested in other people's beliefs and why they might believe it... but I'm not that interested in exploring it for myself"17:31 What and Who Matters?50:02 A Better World?01:27:00 Follow Heather and Michelle:- VinE- VinE on Insta- VinE on LinkedIn- Heather at Edge HillAnd more... full show notes at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Sentientism.info⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.Sentientism is “Evidence, reason & compassion for all sentient beings.” More at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Sentientism.info⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Join our⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠"I'm a Sentientist" wall⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ via⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ this simple form⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.Everyone, Sentientist or not, is welcome in our ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠groups⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. The biggest so far is ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠here on FaceBook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Come join us there!

As our show aired Erev Yom Kippur, we again presented excerpts of our past interviews on The Yiddish Voice/דאָס ייִדישע קול with Holocaust survivors who died during the past year. Since our previous episode, we've lost Ben Lesser, who died the first day of Rosh Hashona, so we were unable to include this in our previous week's show. The remainder of the show is a repeat of the previous week's show. Ben Lesser (died September 23, 2025, age 96) - Ben was a Holocaust Survivor, Author, Lecturer, and visionary founder of The ZACHOR Holocaust Remembrance Foundation. He was known around the world for his courageous testimony, tireless advocacy and unwavering commitment to education and remembrance. Born in Krakow, Poland in 1928 to Shari Segal and Lazar Leser. Ben was the second youngest of five children, Moshe Leser, Lola Lieber-Schwartz, Goldie Leser and baby brother Naphtali Leser. At age ten his life as a boy was forever changed. He endured four concentration camps, a seven-week death march, and two death trains, one of which was the notorious ill-fated death train from Buchenwald to Dachau where of the 6,000 inmates that walked on, only 18 walked off. Ben was the last living survivor from that train. We reached him by Zoom on Apr. 17, 2023. Originally aired April 19, 2023. NOTE: MEMORIAL SERVICE OCT 19 2025: https://templebethsholomlv.shulcloud.com/form/ben-lesser-memorial (for additional show notes, see show notes for last week's episode: https://podcast.yv.org/episodes/remembering-aron-bell-bielski-natan-gipsman-judy-altmann-zoli-langer) Air date: October 1, 2025

Send us a textI am preaching this homily on our pilgrimage in Poland. We visited Auschwitz/Brirkenau camp this morning; we are celebrating Mass in Sanktuarium Pasyjno-Maryjne, where Karol Wojtyra (St. John Paul II) came on pilgrimage as a boy.When I visited Krakow in 2001, we toured the Wawel Cathedral. There's a great bell in the tower, like Big Ben in London. It weighs 11 tons and it takes 12 people to ring it. This bell is named Zygmunt, and it has been rung for every major event in Poland since it was cast in 1520.frjoedailey@gmail.com

Send us a textTeaching, Training and Transformation: Malgorzata's Journey ForwardWhat happens when language that works at home starts changing classrooms and systems. What if a one minute demo with an umbrella could stop symptom punishment faster than another meeting. What if a parent advocate was invited to help shape an international conference.About This EpisodeIn this Part 2 of The FASD Success Show, I bring Malgorzata back from Poland to share what happened next. Invitations to schools and trainings took off. A new film for students was produced for nationwide use. She ran small room foster trainings that created big shifts. She was asked to moderate in Krakow and evaluate research abstracts. And at home her family kept doing the brave work of healing as her son began building real connections with his birth siblings.Meet the Guest: MalgorzataMalgorzata is the founder of FASmisja. What started as one mom searching for answers has grown into a national movement focused on prevention, practical education, and hope for families and professionals.In This Episode You Will Hear• How advocacy scaled from kitchen table to schools, conferences, and national prevention efforts • The student film project, which will Premiere 10.20.2025,  and why short, clear education can move a whole system • Simple teaching tools to borrow now including the umbrella activity and the  chin and cheek demo • Why modeling matters for adults and how kids copy what we do more than what we say • Choosing school fit over labels and the reality of integration settings in Poland • What changed most in a two day foster caregiver training with a small group • A powerful home story of grief and connection as her son visited his birth mother's grave and chose to meet siblings • How she moved past imposter feelings by speaking from the heart and letting results do the talkingWhy It MattersPart 1 showed pain turning into purpose. Part 2 shows purpose turning into progress you can feel in classrooms and communities. You will get tools you can show, not just tell. You will see proof that systems can listen. You will leave steadier for hard conversations at home and clearer about small wins you can create this week.

Savage speaks with Sean McNamara, a renowned Hollywood director, about his career and his latest film, Bau: Artist at War. McNamara has directed acclaimed films, including Soul Surfer, Reagan, and The Last Firefighter. Savage and Sean discuss Savage's role in the The Last Firefighter and behind-the-scenes from the set with Jon Voight and Kelsey Grammer. Sean shares his journey into Hollywood, reminiscing about his start as a paperboy at Disney and eventually working on major projects. The conversation delves deeply into Bau Artist at War, set during the Holocaust, telling the true love story of Joseph and Rebecca Bau in a concentration camp. Sean emphasizes the miracles and hope depicted in the film and how they resonate with contemporary issues. They also discuss the logistics and emotional challenges of filming in Krakow, the involvement of professional actors, and the impact of technological advancements on film production. Savage underscores the significance of seeing the film in theaters to support true stories of resilience and love.

CONTINUED HEADLINE: Global Tensions Escalate: Nuclear Drills, Urban Warfare, and Naval Probes Amidst Shifting Alliances GUEST NAME: Jeff McCausland SUMMARY: Russia conducts tactical nuclear drills with Belarus as drones probe Polish airspace, while Israel engages in difficult urban warfare in Gaza, and the US flexes naval power against Venezuela, all against a backdrop of potential regional miscalculations. Russia's Zapad 2025 includes tactical nuclear training with Belarus, as unidentified drones probe Polish territory. Israel faces six months of challenging urban combat in Gaza, learning from Fallujah. The USconducts naval exercises near Venezuela, potentially aimed at destabilizing Maduro. Regional flashpoints in Syria risk accidental escalation between Turkey and Israel. 1895 KRAKOW

CONTINUED Anatol Lieven explains that Alexander Lukashenko of Belarus is a Soviet loyalist, not a Putin stooge, but was driven to Russia by Western sanctions. He discusses Russian drone incursions into Poland, likely an intentional message to NATO to test air defenses and warn against deploying troops to Ukraine. Russia may also seek to maintain Belarus firmly in its orbit by disrupting its multi-vector foreign policy initiatives, particularly any attempts at détente with the West. 1895 KRAKOW